Related Experiment Video
Updated: Apr 23, 2026
10:33
Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow
Published on: January 8, 2014
6.3K
Upstream and downstream processing of recombinant IgA
David Reinhart1, Renate Kunert
1Department of Biotechnology, Vienna Institute of BioTechnology, University of Natural Resources and Life Sciences, Muthgasse 11, 1190, Vienna, Austria, david.reinhart@boku.ac.at.
Biotechnology Letters
|September 27, 2014
Summary
Recombinant Immunoglobulin A (IgA) production for therapies faces challenges in large-scale manufacturing. This review details advancements and hurdles in producing and purifying IgA for therapeutic applications.
Area of Science:
- Biotechnology
- Immunology
- Biopharmaceutical Manufacturing
Background:
- Immunoglobulin A (IgA) is crucial for mucosal immunity and shows therapeutic promise for infectious and malignant diseases.
- Therapeutic development of IgA is hindered by challenges in producing and purifying sufficient quantities for research and clinical use.
Purpose of the Study:
- To review current biotechnological achievements and bottlenecks in the upstream and downstream processing of recombinant IgA.
- To highlight diverse expression systems and compare affinity techniques for recombinant IgA purification.
Main Methods:
- Review of current literature on recombinant IgA production.
- Analysis of upstream (expression) and downstream (purification) processing strategies.
- Comparison of various affinity chromatography techniques for IgA capture.
Main Results:
- Identified key challenges in large-scale recombinant IgA production and purification.
- Highlighted progress in diverse expression systems for IgA.
- Evaluated the purification potential of different affinity techniques for recombinant IgA.
Conclusions:
- Overcoming production and purification challenges is essential for realizing the therapeutic potential of IgA.
- Advancements in expression systems and purification technologies are critical for enabling IgA-based therapies.
- Further optimization of recombinant IgA manufacturing processes is required for in vivo studies and clinical applications.
Related Concept Videos
01:27Upstream Processing
95
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
95
01:15Transcytosis of IgG
3.4K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.4K
01:20Immunoprecipitation
5.5K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.5K
01:23Vaccine Production
120
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
120
01:30Production of Pharmaceuticals
90
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
90